Medtronic plc is an American medical device company. The companys operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015.
Company profile
Ticker
MDT
Exchange
Website
CEO
Geoffrey Martha
Employees
Location
Fiscal year end
Industry (SIC)
Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • GigCapital5 • Outset Medical • Fonar ...
Former names
Medtronic Holdings Ltd, Medtronic Ltd
SEC CIK
Corporate docs
Subsidiaries
2074417 Alberta ULC • A&E Products de Honduras S.A. • A&E Products do Brasil Ltda. • A&E Products Group, Inc. • Advanced Medical Technologies GmbH • Affera, Inc. • AI Biomed Corp • Aircraft Medical Ltd. • Airox, Inc. • Arterial Vascular Engineering Canada, Company ...
MDT stock data
Analyst ratings and price targets
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
13 Sep 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
31 Aug 23
10-Q
2024 Q1
Quarterly report
31 Aug 23
8-K
Medtronic reports first quarter
22 Aug 23
DEFA14A
Additional proxy soliciting materials
11 Aug 23
DEF 14A
Definitive proxy
11 Aug 23
8-K
Medtronic Board appoints Greg Lewis as new Director
26 Jun 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
22 Jun 23
10-K
2023 FY
Annual report
22 Jun 23
SD
Conflict minerals disclosure
30 May 23
Transcripts
MDT
Earnings call transcript
2024 Q1
22 Aug 23
MDT
Earnings call transcript
2023 Q4
25 May 23
MDT
Earnings call transcript
2023 Q3
21 Feb 23
MDT
Earnings call transcript
2023 Q2
22 Nov 22
MDT
Earnings call transcript
2023 Q1
23 Aug 22
MDT
Earnings call transcript
2022 Q4
26 May 22
MDT
Earnings call transcript
2022 Q3
22 Feb 22
MDT
Earnings call transcript
2022 Q2
23 Nov 21
MDT
Earnings call transcript
2021 Q2
24 Aug 21
MDT
Earnings call transcript
2021 Q4
27 May 21
Latest ownership filings
4
Gregory L Smith
25 Aug 23
144
Notice of proposed sale of securities
23 Aug 23
4
Brett A. Wall
16 Aug 23
144
Notice of proposed sale of securities
14 Aug 23
4
Michael Marinaro
7 Aug 23
4
Jennifer M Kirk
7 Aug 23
4
ROBERT JOHN WHITE
7 Aug 23
4
Brett A. Wall
7 Aug 23
4
HOEDT ROB TEN
7 Aug 23
4
Gregory L Smith
7 Aug 23
Financial summary
| Quarter (USD) | Jul 23 | Apr 23 | Jan 23 | Oct 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Apr 23 | Apr 22 | Apr 21 | Apr 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.34 bn | 1.34 bn | 1.34 bn | 1.34 bn | 1.34 bn | 1.34 bn |
| Cash burn (monthly) | 68.00 mm | 66.75 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 136.13 mm | 133.63 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 1.20 bn | 1.21 bn | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 17.7 | 18.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2023
79.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1908 |
| Opened positions | 165 |
| Closed positions | 137 |
| Increased positions | 824 |
| Reduced positions | 714 |
| 13F shares | Current |
|---|---|
| Total value | 92.78 tn |
| Total shares | 1.06 bn |
| Total puts | 4.51 mm |
| Total calls | 4.84 mm |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 125.84 mm | $11.09 tn |
| BLK Blackrock | 114.95 mm | $10.13 tn |
| STT State Street | 60.15 mm | $5.34 tn |
| Massachusetts Financial Services | 36.00 mm | $3.17 tn |
| Capital Research Global Investors | 31.49 mm | $2.77 tn |
| Geode Capital Management | 25.62 mm | $2.25 tn |
| BAC Bank Of America | 25.43 mm | $2.24 tn |
| Wellington Management | 24.48 mm | $2.16 tn |
| MS Morgan Stanley | 21.78 mm | $1.92 tn |
| BK Bank Of New York Mellon | 19.88 mm | $1.75 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Aug 23 | Gregory L Smith | Ordinary Shares | Sell | Dispose S | No | No | 83.84 | 10,000 | 838.40 k | 46,723 |
| 14 Aug 23 | Brett A. Wall | Ordinary Shares | Sell | Dispose S | No | Yes | 83.38 | 1,000 | 83.38 k | 33,573 |
| 3 Aug 23 | Geoffrey Martha | Ordinary Shares | Payment of exercise | Dispose F | No | No | 84.49 | 17,965 | 1.52 mm | 141,144 |
| 3 Aug 23 | Geoffrey Martha | Ordinary Shares | Grant | Acquire A | No | No | 0 | 18,165 | 0.00 | 159,109 |
| 3 Aug 23 | Geoffrey Martha | Performance Share Units Performance Share Unit | Option exercise | Dispose M | No | No | 0 | 18,165 | 0.00 | 0 |
| 3 Aug 23 | Parkhill Karen L | Ordinary Shares | Payment of exercise | Dispose F | No | No | 84.49 | 5,919 | 500.10 k | 46,327 |
| 3 Aug 23 | Parkhill Karen L | Ordinary Shares | Grant | Acquire A | No | No | 0 | 7,105 | 0.00 | 52,246 |
| 3 Aug 23 | Parkhill Karen L | Performance Share Units Performance Share Units | Option exercise | Dispose M | No | No | 0 | 7,105 | 0.00 | 0 |
| 3 Aug 23 | Sean Salmon | Ordinary Shares | Payment of exercise | Dispose F | No | No | 84.49 | 4,369 | 369.14 k | 47,726 |
| 3 Aug 23 | Sean Salmon | Ordinary Shares | Grant | Acquire A | No | No | 0 | 5,604 | 0.00 | 52,095 |
News
Medtronic Diabetes Announces CE Mark For New Simplera CGM With Disposable All-In-One Design
21 Sep 23
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
13 Sep 23
Looking Into Medtronic's Recent Short Interest
12 Sep 23
Peering Into Medtronic's Recent Short Interest
25 Aug 23
Investor Caution - Medtronic's Rocky Road Ahead For Hypertension Device
24 Aug 23
Press releases
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
26 Sep 23
NeurAxis Stock Has 236% Upside Says GSCR Analyst, Fueled By Drug-Free IB-Stim Technology To Treat Pediatric Irritable Bowel Syndrome ($NRXS)
26 Sep 23
Medtronic Diabetes announces CE Mark for new Simplera™ CGM with disposable all-in-one design
21 Sep 23
Analyst Models NeurAxis 12-Month Share Price Target At $14, 301% Higher Than Current Price ($NRXS)
21 Sep 23
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
19 Sep 23